Compare Medpace Holdings Inc (MEDP) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Teladoc Health Inc — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while Teladoc Health Inc trades at $9.78 (market cap $1.74B). The key difference: Medpace Holdings Inc is far larger — about 8.7× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | TDOC | |
|---|---|---|
Market Cap | $15.08B | $1.74B |
Sector | Technology | Health |
52-Week High | $620.59 | $9.72 |
52-Week Low | $308.88 | $4.47 |
Enterprise Value | $14.55B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
TDOC trades at $9.63, up 2.12% today, with a bullish technical signal from moving averages and a neutral RSI near 60. Revenue remains stable around $2.5 billion, but net losses persist with a -6.81% margin. Recent news highlights expansion through the Walmart partnership and upcoming Q2 2026 earnings. The stock shows resilience despite negative profitability, supported by a low P/S ratio of 0.67 and improving cash flow trends from operations.
Outlook is mixed: cost-cutting and partnerships offer growth potential, but sustained losses and high debt pose risks. Analysts are cautious with a $8.75 price target below current levels, reflecting concerns over profitability. Investors should weigh the recovery narrative against financial challenges, with earnings on July 29, 2026, as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
